U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06971276) titled 'Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening' on May 05.
Brief Summary: The study is to test a liquid biopsy assay for screening and classifying anal dysplasia from blood.
Study Start Date: April 03, 2024
Study Type: OBSERVATIONAL
Condition:
Anal Dysplasia
Recruitment Status: RECRUITING
Sponsor: Massachusetts Eye and Ear Infirmary
Information provided by (Responsible Party): Daniel L. Faden, MD, Massachusetts General Hospital
Disclaimer: Curated by HT Syndication....